The Asthma and COPD Therapies Market Will Reach $35.87bn in 2019

Monday 28 November 2016, Amsterdam

A new report, now available on ASDReports, predicts that the Latin Asthma and COPD Therapies market will reach $35.87bn in 2019. This forecast and others appear in Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies, published in October 2015.

The Asthma and COPD Therapies Market 2015-2025 report examines the current and future pharmaceutical treatments for these two respiratory diseases. Both of these diseases require complex treatment regimes and cause significant quality of life impairments for patients. With reported numbers for both asthma and COPD showing growth all over the world, understanding the market and the treatments available is crucial for all those in fields related to the sector.

In this report, we examine in detail a number of key national markets, as well as the sales of a wide range of leading treatments in the following asthma and COPD submarkets: bronchodilator monotherapy (including SABAs, LABAs and anticholinergics), anti-inflammatory drugs (including corticosteroids, anti-leukotrienes and monoclonal antibodies) and combination drugs. Additionally, forecasts are provided for 27 therapies including 5 promising pipeline candidates. Using both primary and secondary research, forecasts have been built for both national markets and treatments, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Also included is analysis of the current leading players in the asthma and COPD therapies market. This includes a look at their current products, as well those presently in development. Revenues for each company are forecast until 2025, with an analysis of news that may influence the course of the company. This leads into the pipeline analysis, where treatments currently in development but may be introduced to the market in the next few years are studied and evaluated.

Jack Evans, a pharmaceutical and medical devices industry analyst and consultant, said: “The entry of generic versions of best selling products will lead to slow growth for the next few years, but the introduction of new combination products and monoclonal antibodies will reverse this trend. These products will demand high prices and result in significant returns for the companies that have developed them.”

This report provides revenue forecasts to 2025 for the Asthma and COPD Therapies market and its leading national markets. The report discusses selected leading companies hold significant shares of the market. These companies include GSK, Boehringer Ingelheim, AstraZeneca, Merck, Roche and Teva. This report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.